This was the stock's fourth consecutive day of losses.

This was the stock's third consecutive day of losses.

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.10% of ...

A small study published Monday found that the COVID-19 antiviral treatment Paxlovid may have use as a treatment for long ...

After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...

Galapagos will gain full development and commercialization rights to its pipeline, and is subject to single digit royalty ...

According to Benzinga Pro, Gilead Sciences's peer group average for short interest as a percentage of float is 5.13%, which ...

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...

TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy ...

Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,101.15 today based on a ...

CWA Asset Management Group LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 1.5% in ...